Influence of time to treatment, on early infarct-related artery patency after different thrombolytic regimens

Background In an in vitro model, recombinant tissue-type plasminogen activa tor was significantly more effective than streptokinase in dissolving 24-ho ur-old human blood clots. Therefore there might be a difference in the effe ct of time to treatment on the efficacy of these fibrinolytics with differe nt fibrin specificity in patients with acute myocardial infarction. Methods and Results The effect of the interval between symptom onset and in itiation of therapy on the efficacy of 6 different thrombolytic regimens wa s studied in a retrospective analysis of 6 angiographic trials with similar design. The potency of the infarct-related artery was assessed by angiogra phy 90 minutes after initiation of thrombolysis in patients who were seen w ithin 6 hours after symptom onset. Patency rates of patients with an interv al of less than or equal to 3 hours and >3 hours between symptom onset and start of therapy were compared. There was no difference for Thrombolysis in Myocardial Infarction (TIMI) grade 3 perfusion after front-loaded alteplas e (72.5% vs 76.3%) and reteplase (63.6% vs 63.2%) between the 2 groups. In contrast, in patients treated with streptokinase (36.8% vs 27.6%, P = .09), anisoylated plasminogen streptokinase activator complex (59.5% vs 34.8%, P = .004), and urokinase (62.3% vs 41.7%, P = .03), TIMI 3 patency decreased with the increasing interval between symptom onset and initiation of thera py. Conclusions We conclude from our data that the thrombolytic efficacy of rec ombinant tissue-type plasminogen activator and reteplase does not decrease with the increasing interval between symptom onset and initiation of therap y. In contrast, after anisoylated plasminogen streptokinase activator compl ex, streptokinase, and urokinase treatment, a decrease in patency, especial ly TIMI-3 patency in patients treated after >3 hours after symptom onset, w as observed. These results may influence the choice of the thrombolytic age nt in patients who are seen >3 hours after symptom onset.